Transverse Medical

What Transverse Medical does

Transverse Medical Inc. is a privately held, pre-commercial medical device company developing a single core product: the POINT-GUARD™ Cerebral Embolic Protection device, a filter-based catheter system intended to capture embolic debris released during structural heart procedures such as Transcatheter Aortic Valve Replacement (TAVR). The device is designed to provide full-brain protection by covering all great arch vessels, positioning it against the single partially-protective cerebral embolic protection device currently on the market, and to do so with operator ease of use and non-interference with other procedural tools. The intended clinical benefit is reduction of periprocedural stroke and silent stroke — reported at rates as high as 9% in unprotected TAVR patients — which the company ties to both improved patient outcomes and lower healthcare system costs.

The company is investigational-stage: POINT-GUARD is limited by US federal law to investigational use and has not been cleared for sale by any regulatory authority domestically or internationally. A feasibility clinical study was completed in April 2025 at the Victorian Heart Hospital in Melbourne, Australia, representing the first in-human use of the next-generation device; broader pivotal studies and FDA clearance (likely a PMA pathway) remain ahead. The business model is a straightforward medical-device hardware sale: once cleared, the company intends to commercialize through direct hospital field sales targeting interventional cardiology and cardiac surgery departments performing structural heart procedures. Pricing has not been publicly disclosed, and there are no recurring software, service, or consumable revenue streams described in the available data.

Operationally, Transverse Medical is small (1–10 employees, headquartered in Golden, Colorado) and venture-backed, having closed a Series B1 in August 2023 (~$6.6M) and a Series B2 in April 2025 (~$10M). The company has been actively building executive and board bench strength in preparation for commercialization — adding a CFO in June 2026 and recruiting senior board talent with deep enterprise-medtech and capital-markets pedigree. The company has no disclosed customers, no revenue, and no commercial distribution infrastructure today; all growth-stage operating activity (clinical, regulatory, fundraising, executive hiring) is directed toward reaching first regulatory clearance and commercial launch.

Name

Transverse Medical

Legal name

Transverse Medical Inc.

Website

https://transversemedical.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Transverse Medical is a pre-commercial medical device company developing the POINT-GUARD™ Cerebral Embolic Protection device, a filter-based catheter designed to reduce periprocedural stroke during structural heart procedures such as TAVR for hospital-based interventional cardiology and cardiac surgery customers.

Ownership category

akta.pro rank

Product category

Cerebral Embolic Protection Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Cerebral embolic protection
• Structural heart devices
• Stroke prevention devices
• Transcatheter valve protection
• Cardiovascular medical devices

Headquarters

HQ city

Golden

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. POINT-GUARD Device Sales: Pre-revenue company. The company is developing the POINT-GUARD cerebral embolic protection device for commercial sale to hospitals and interventional cardiology centers upon regulatory clearance. The device is currently investigational and not cleared for sale by any regulatory authority.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Transverse Medical is a medical device company developing the POINT-GUARD Cerebral Embolic Protection device, a filter-based full-brain protection solution designed to capture and filter cerebral embolic debris (particles) during cardiovascular procedures such as Transcatheter Aortic Valve Replacement (TAVR). The device is investigational and limited by U.S. federal law to investigational use, not yet cleared for sale by any regulatory authority, foreign or domestic.

Product overview

Transverse Medical is a medical device company with a single core product offering: the POINT-GUARD™ Cerebral Embolic Protection device. This device is designed to provide full brain protection during structural heart procedures, particularly Transcatheter Aortic Valve Replacement (TAVR), by filtering cerebral embolic debris to reduce stroke risk. The product is investigational and has not been cleared for sale by any regulatory authority.

Differentiator

Problem solved

Functional benefit

Brands

• POINT-GUARD PRO: Cerebral embolic protection device designed to reduce stroke risk during structural heart procedures, providing full-brain protection during cardiovascular procedures such as TAVR.
• POINT-GUARD

Products and services

• POINT-GUARD Cerebral Embolic Protection Device

Quantifiable outcome

• Periprocedural stroke rate reported as high as 9% for unprotected patients undergoing TAVR procedures
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and key.

• Victorian Heart Hospital, Melbourne, AustraliacoreStrategic or Co-development Partner · 1 April 2025Transverse Medical collaborated with Victorian Heart Hospital in Melbourne, Australia for the completion of the first series of patients in its feasibility clinical study using the Point-Guard Cerebral Embolic Protection device. The Victorian Heart Hospital was conceived and developed under the leadership of Professor Ian T. Meredith, who served as the principal driving force and chief medical advocate for the hospital's concept, design, and planning.
• Ian T. Meredith, MD (Boston Scientific)keyOthers · 1 October 2024Professor Ian T. Meredith, former Executive Vice President and Global Chief Medical Officer at Boston Scientific (a fortune 200 global medical device company with over 40,000 employees), joined the Transverse Medical Board of Directors in October 2024. He provides clinical innovation, preclinical science, medical affairs expertise, and R&D strategy guidance. He was awarded an Order of Australia (AM) in 2012 for outstanding service to medicine in cardiology.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Boston Scientific: Boston Scientific commercializes the Sentinel Cerebral Embolic Protection device, the only currently approved CEPD for TAVR. Direct competitor to POINT-GUARD in the same hospital-based structural heart procedure channel.
• Silk Road Medical: Silk Road Medical commercializes the ENROUTE neuroprotection system for carotid stenting. Direct peer in vascular embolic protection with a comparable single-product, hospital-channel commercial model.

Broad incumbents

• Edwards Lifesciences: Edwards Lifesciences is the TAVR market leader with the Sapien valve platform. They drive structural heart procedure volumes in which POINT-GUARD would be deployed as an adjunct device and represent the dominant channel partner/customer dynamic.
• Medtronic: Medtronic competes in TAVR with the Evolut platform and is a large cardiovascular device incumbent. Comparable as a structural heart ecosystem participant and potential commercial counterparty for embolic protection.
• Abbott: Abbott is a diversified cardiovascular device leader with structural heart and vascular franchises. Comparable as a broad incumbent whose installed hospital relationships and procedure economics shape the CEPD market.
• MicroPort Scientific: MicroPort is a global cardiovascular and structural heart device manufacturer with TAVR and related franchises. Comparable as a broad incumbent shaping the structural heart ecosystem in which POINT-GUARD would be used.

Emerging players

• InspireMD: InspireMD is developing next-generation embolic protection and carotid stent technologies. Comparable as a smaller competitor in the embolic protection space targeting similar clinical indications.
• Penumbra: Penumbra is a neurovascular device company with stroke treatment and aspiration technologies. Comparable as an emerging neurovascular specialist with overlapping clinical customers and stroke prevention themes.
• Keystone Heart: Keystone Heart developed the TriGuard cerebral embolic protection device for TAVR, an early CEPD competitor that was acquired. Comparable as a focused CEPD peer that pursued similar clinical positioning.
• Lumen Biomedical: Lumen Biomedical is a privately held company developing embolic protection devices for cardiovascular procedures. Comparable as a niche competitor targeting similar cerebral embolic protection indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/transverse-medical-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transverse Medical